Astellas Pharma Inc. ALPMY · Stock Open Astellas Pharma Inc. in new tab
Astellas Pharma Inc. Analysis (ALPMY)
Is Astellas Pharma Inc. a good investment? Astellas Pharma Inc. (ALPMY) is currently trading at 13.42 USD.
In terms of valuation, the stock trades at a P/E ratio of 13.23. This relatively low multiple may signal that Astellas Pharma Inc. is undervalued compared to historical market norms.
Earnings Schedule: Astellas Pharma Inc. is expected to release its next earnings report on July 29, 2026. The market consensus estimate for Forward EPS is 0.45.
For income investors, Astellas Pharma Inc. pays a dividend yield of 3.64%. With a payout ratio of 47%, the dividend appears sustainable.
Investor FAQ
Does Astellas Pharma Inc. pay a dividend?
Yes, it pays an annual dividend of 78.00 USD (3.64% yield).
What asset class is Astellas Pharma Inc.?
Astellas Pharma Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be July 29, 2026. The company currently has a trailing EPS of 1.02.
Company Profile
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy secondary to age-related macular degeneration; EVRENZO, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It has a research collaboration with xFOREST Therapeutics to develop RNA-targeted therapies and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize an integrated diabetes self-management solution. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
| Year | Total Dividends |
|---|---|
| ▸2026 |
0.69 USD
|
| Dec. 16, 2026 (estimated) | 0.2397 |
| June 3, 2026 | 0.2069 |
| June 3, 2026 | 0.2444 |
| ▸2025 |
0.49 USD
|
| Dec. 16, 2025 | 0.2316 |
| June 3, 2025 | 0.2570 |
| ▸2024 |
0.32 USD
|
| Dec. 17, 2024 | 0.1669 |
| June 17, 2024 | 0.1516 |
| ▸2023 |
0.32 USD
|
| Dec. 18, 2023 | 0.1678 |
| June 16, 2023 | 0.1533 |
| ▸2022 |
0.29 USD
|
| Dec. 15, 2022 | 0.1561 |
| June 15, 2022 | 0.1371 |
| ▸2021 |
0.36 USD
|
| Sept. 29, 2021 | 0.2204 |
| June 16, 2021 | 0.1423 |
| ▸2020 |
0.28 USD
|
| Dec. 15, 2020 | 0.1425 |
| June 15, 2020 | 0.1362 |
| ▸2019 |
0.28 USD
|
| Dec. 17, 2019 | 0.1569 |
| July 5, 2019 | 0.1271 |
| ▸2018 |
0.33 USD
|
| Dec. 17, 2018 | 0.1673 |
| July 3, 2018 | 0.1629 |
| ▸2017 |
0.31 USD
|
| Dec. 18, 2017 | 0.1607 |
| July 5, 2017 | 0.1524 |
| ▸2016 |
0.30 USD
|
| Dec. 15, 2016 | 0.1488 |
| July 1, 2016 | 0.1530 |
| ▸2015 |
0.26 USD
|
| Dec. 16, 2015 | 0.1302 |
| July 6, 2015 | 0.1300 |
| ▸2014 |
0.29 USD
|
| Dec. 18, 2014 | 0.1185 |
| July 3, 2014 | 0.1718 |
| ▸2013 |
0.82 USD
|
| Dec. 17, 2013 | 0.1578 |
| July 8, 2013 | 0.6651 |
| ▸2012 |
1.60 USD
|
| Dec. 18, 2012 | 0.7893 |
| July 9, 2012 | 0.8101 |
| ▸2011 |
1.58 USD
|
| Dec. 16, 2011 | 0.7720 |
| July 7, 2011 | 0.8109 |
| ▸2010 |
1.44 USD
|
| Dec. 16, 2010 | 0.7112 |
| July 12, 2010 | 0.7270 |
| ▸2009 |
1.32 USD
|
| Dec. 16, 2009 | 0.6906 |
| July 9, 2009 | 0.6292 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Astellas Pharma Inc. | Jun 03, 2026 | Paid | 0.2069 USD |
| Astellas Pharma Inc. | Jun 03, 2026 | Paid | 0.24439 USD |
| Astellas Pharma Inc. | Dec 16, 2025 | Paid | 0.23164 USD |
| Split Date | Split Ratio to 1 |
|---|---|
| April 2, 2014 | 1.250000 |
| May 13, 2013 | 4.000000 |
Community Discussion